I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche at

ECP 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Sep 9 / Roche
Comparison of data from two commercially available tissue-based comprehensive genomic profiling (CGP) solutions using AMP/ASCO/CAP guidelines and ESMO ESCAT
This study compared differences in data generated by the AVENIO Tumor Tissue CGP Kit and the TruSight Oncology 500 (TSO) assay - two commercially available pan-cancer solutions. Potential clinical implications of the data generated by both products is presented. Variant calls were acquired using manufacturer-provided software; key variant annotation outputs were variant tiers and ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) guideline inclusion per tumour type. Differences in the detection of tumour mutational burden and ESCAT biomarkers, including copy number alterations, were identified.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 9 / Roche
Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples for Patient Identification in Two Phase 3 Trials of Zolbetuximab
Study evaluating the performance of the investigational VENTANA CLDN18 (43-14A) RxDx Assay for IHC detection of CLDN18.2 to help identify patients with LA unresectable or mG/GEJ adenocarcinoma who could possibly benefit from zolbetuximab therapy in the SPOTLIGHT and GLOW trials.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 9 / Roche
Predicting Cell-of-origin for Diffuse Large B-cell Lymphoma Patients (DLBCL) using Explainable Feature Based Model
This study compares use of two deep learning models for cell of origin classification of whole slide images of haematoxylin and eosin-stained pathology slides from patients with diffuse large B-cell lymphoma and identifies cellular features that impact on model prediction.